Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

Nektar Announced Results for NKTR-358 
During an oral session at the Annual European Congress of Rheumatology (EULAR) 2019, in Madrid, Nektar Therapeutics (NKTR) announced results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358 for the treatment of autoimmune and other chronic inflammatory conditions. 

The . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.